LPL Financial LLC and its former financial advisor, Eileen Law Cure, have been brought into sharp focus following recent regulatory actions and a string of customer complaints. In an industry where trust is paramount and every dollar represents an investor’s future, this case serves as a timely reminder of the importance of due diligence. As Benjamin Franklin famously said, “An investment in knowledge pays the best interest.”
Eileen Law Cure: Regulatory Actions and Customer Complaints
Eileen Law Cure (also known simply as Eileen Cure), formerly registered under CRD #2224269, has recently faced increased scrutiny. According to information reviewed as of June 11, 2026 on FINRA BrokerCheck, Cure has a significant regulatory action on her record, along with five customer dispute disclosures—a combination that few investors can afford to ignore.
The most consequential event occurred on May 5, 2026, when the Financial Industry Regulatory Authority (FINRA) issued an indefinite suspension against Eileen Law Cure in all professional capacities. This decisive action was not arbitrary: it followed her alleged failure to comply with a binding arbitration award or settlement agreement, and her lack of satisfactory response to FINRA’s inquiries about her compliance status. The arbitration case, which involved LPL Financial LLC, resulted in Cure being ordered to pay compensatory damages, interest, attorneys’ fees, and FINRA fees. Unlike a temporary measure, an indefinite suspension is a severe consequence that signals significant professional concern.
A Pattern of Customer Disputes: Examining the Details
The story does not end there. Eileen Law Cure’s regulatory record includes five customer dispute settlements, highlighting repeated client concerns. Let’s review two of the most notable cases:
- August 20, 2024: A customer alleged that Cure recommended an unsuitable Direct Investment-DPP & LP Interest, originally purchased in 2015. The claimant sought $25,000 in damages; the matter was settled for $11,250 on February 7, 2025.
-
May 13, 2024: Another dispute alleged unsuitable investment recommendations and misrepresentation involving real estate securities and business development companies (BDCs). The client sought damages between $100,000 and $500,000. This resulted in two settlements:
- $30,000 settled on July 18, 2025
- $20,000 settled on June 5, 2025
In addition to these cases, three further customer disputes were also reported and settled. Complaints filed between 2012 and 2023 centered on issues such as unsuitable portfolio allocations, misrepresentation of private placements, excessive concentration in single positions, structured note misrepresentation, and disputes concerning municipal bond laddering. Settlement amounts in these cases reportedly ranged between $125,000 and $225,000—substantial sums that reflect real losses for investors who put trust in their financial advisor.
A consistent presence of customer disputes and a regulatory suspension for non-compliance reflect a pattern that demands careful attention. For investors, these disclosures should serve as critical warning signs about the risks of inadequate due diligence.
Eileen Law Cure: Background and Registration History
Understanding the professional journey of Eileen Law Cure provides essential context. Cure began her financial services career in 1996 and passed several important industry examinations, including:
- Securities Industry Essentials (SIE) – passed 2018
- Series 7 – passed 1996
- Series 63 – passed 1996
- Series 65 – passed 2010
Her employment history includes registrations with several prominent broker-dealers:
- Merrill Lynch, Pierce, Fenner & Smith Incorporated
- Investment Management & Research, Inc.
- HD Vest Investment Services
- LPL Financial LLC (her most recent employer, terminated May 2026)
As of June 11, 2026, Cure is not registered with any FINRA member firm—a status with significant implications for investors relying on her advice or previous recommendations.
What the Statistics Say: The Risk of Misconduct Among Advisors
Research by the University of Chicago found that approximately 7% of financial advisors have a history of misconduct. Notably, those with past disclosures are five times more likely to engage in future misconduct than their clean-record peers. This means that repeated complaints, as seen in Eileen Law Cure’s case, are not outliers—they are serious red flags that should give investors pause and prompt closer scrutiny. For more insight into investment advisory complaints, visit Financial Advisor Complaints.
No Securities and Exchange Commission (SEC) enforcement actions, criminal disclosures, or bankruptcy filings are shown on Cure’s record. However, the regulatory suspension and volume of settled customer complaints remain public concerns.
FINRA Rules and Suitability: What Went Wrong
The regulatory framework overseeing brokers is robust—and for good reason. Two specific FINRA rules are central to the issues surrounding Eileen Law Cure:
- FINRA Rule 9554: This rule allows FINRA to suspend brokers who fail to comply with arbitration awards or settlements. If an advisor ignores a legal or financial obligation to a client and fails to respond to regulatory inquiries, FINRA takes action to protect investors’ interests.
- FINRA Rule 2111 (Suitability): Suitability means that brokers must tailor recommendations based on a customer’s risk tolerance, financial situation, investment objectives, experience, and time horizon. Multiple disputes against Cure reference unsuitable recommendations—especially in alternative assets and complex securities.
Additionally, the SEC’s Regulation Best Interest (Reg BI), which became effective June 30, 2020, obligates advisors to act in the best interests of their clients by recommending the most suitable products, disclosing conflicts, and prioritizing clients’ interests above their own incentives. To learn more about the practical impact of Reg BI, you can read Regulation Best Interest Explained on Investopedia.
Investment Fraud and Adviser Misconduct: The Bigger Picture
America’s investors lose billions of dollars each year to investment fraud and bad financial advice. The North American Securities Administrators Association (NASAA) notes that common schemes include unsuitable product recommendations, misrepresentations, and outright fraud—often perpetuated by individuals with a record of past complaints or regulatory actions.
A Forbes article highlights how unsuitable investments and misleading advice are consistently among the top investor complaints. Many such cases involve advisors steering clients into high-commission products or risky, illiquid investments that do not align with their needs—concerns echoed in Cure’s complaint history.
Practical Lessons for Investors: How to Protect Yourself
The story of Eileen Law Cure is more than a single advisor’s professional downfall—it’s a wake-up call to anyone entrusting their savings to a financial professional. Here are a few essential steps to safeguard your financial future:
- Check regulatory records before hiring a financial advisor. Use free resources like FINRA BrokerCheck to review complaints
Correction or Updated Info Needed? The information in this article includes the publisher's opinion and is based on publicly available materials believed to be accurate at the time of publication.
We welcome updates. If you have personal knowledge of additional facts or details related to any issues or individuals, and you believe that information would enhance the accuracy of the article, don't hesitate to get in touch with us https://financialadvisorcomplaints.com/article-correction-update/ and provide you name, address, email, and telephone contact for follow-up reporting, along with the back-up for any updates. The publisher strives to provide the most up-to-date and most accurate report regarding all issues and events, and welcomes input from any individuals with personal knowledge.
DISCLAIMER: The information herein is derived from public sources and is provided "as is" without warranty of any kind. Legal matters may have subsequent developments, and market values may fluctuate. While we strive for accuracy, we make no representations about the completeness or reliability of this information. Readers should independently verify all content and seek professional advice as needed.
